Navigation Links
TOMA Biosciences Releases the COMPASS Tumor Profiling System
Date:3/30/2017

American Association for Cancer Research (AACR) Annual Meeting 2017

TOMA Biosciences launches the COMPASS Tumor Profiling System™ - a simple and efficient workflow pathway from tumor, library preparation, sequencing, data analysis, clinical annotation, through reporting. Now, clinical researchers have everything they need to find clinically meaningful changes in tumor DNA.

The core of the COMPASS Tumor Profiling System is the Oligo Selective Sequencing capture assay, TOMA OS-Seq™, a patented technology invented at Stanford University. TOMA OS-Seq delivers unparalleled uniform sequence data of cancer genes from damaged DNA present in FFPE tumor specimens. The core offering of COMPASS allows the capture of tumor DNA from 130 cancer genes and can be customized to any genes of interest.

The COMPASS Tumor Profiling System includes:

  • a comprehensive set of DNA library preparation reagents
  • reference materials to assess sensitivity and specificity for validation
  • proprietary sequence data analysis software for somatic variant identification
  • options for annotation and reporting

COMPASS data analysis is performed through TOMA Stratus™. Stratus is a simple to use, cloud-based service with a web interface to easily upload data and download results. Within Stratus, COMPASS Analysis uses a proprietary method constructed to identify changes specific to the tumor DNA and removes inherited changes that many laboratories report without a specific somatic link.

COMPASS is a complete solution for clinical researchers looking to implement cancer genomics with superior performance while reducing cost and complexity.

“Our team set out to build a simple and complete solution for clinical researchers to analyze tumor DNA and produce actionable findings; with COMPASS they have achieved that aim.” said Wolfgang Daum, TOMA President and CEO.

“Finally, clinical researchers have what they need to simplify operations, improve accuracy and reduce costs. COMPASS can be implemented by clinical researchers and validation-ready in under a week.” commented Dr. Daum.

In addition to the core offering which includes the reagents, reference materials, and secondary analysis software, COMPASS enables several downstream interpretation options for clinical researchers, including access to curated clinical annotation information and reporting tools.

"FOR RESEARCH USE ONLY"

To learn more: attend ‘From Tumor to Action’ webinar.

About TOMA Biosciences
TOMA Biosciences Inc. is a genomics information company and the developer of the COMPASS Tumor Profiling System. COMPASS makes cancer genomics simple. The system includes everything a clinical laboratory needs to detect genomic changes in tumors including many missed by other methods. With its core sequencing technology invented at Stanford University, TOMA Biosciences provides a comprehensive solution to prepare tumor DNA for sequencing and reveal somatic variants. The company is led by innovative scientists, clinicians and technology developers to enable clinical laboratories, hospital systems and research institutions around the world to do cancer genomics. Headquartered in Foster City California, TOMA Biosciences is a commercial stage, private venture-backed company.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14194517.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
2. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
3. Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
4. Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
5. DuPont Industrial Biosciences Leader Presents Major Advances in Biomaterials at 2017 Advanced Bioeconomy Leadership Conference
6. Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation
7. ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
8. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
9. Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
10. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
11. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):